News
Sarepta, FDA and Gene
Digest more
Sarepta Therapeutics suffered another major setback on Friday as Europe's drug regulator decided not to recommend the ...
This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy ...
Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...
Zacks.com on MSN4d
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy ProgramSarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
FDA may face scrutiny This latest incident casts a shadow over Elevidys, Sarepta’s flagship therapy, and may increase scrutiny of the U.S. Food and Drug Administration’s decision to approve ...
FDA confirms two fatal cases of liver failure in DMD patients treated with Elevidys HC Wainwright reiterates Sell rating on Sarepta, with a $10 price target Tim Melvin’s system has spotted 10X ...
A Massachusetts biotechnology company is laying off 21 employees in Durham amid a broader restructuring and pressure from federal regulators.
Biotech firm Sarepta Therapeutics said that a second patient died after receiving its gene therapy to treat Duchenne muscular dystrophy, the latest drug to draw scrutiny after winning fast ...
FDA may face scrutiny This latest incident casts a shadow over Elevidys, Sarepta’s flagship therapy, and may increase scrutiny of the U.S. Food and Drug Administration’s decision to approve ...
The drug, which was designed to treat Duchenne muscular dystrophy, has been linked to the deaths of two teenage boys.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback